At Zogenix, our core strategy is to commercialize and develop differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs and overcome limitations of existing products.

Zogenix, Inc. is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Our first commercial product, SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache.

Our lead investigational product candidate, Zohydro (hydrocodone bitartrate), is a novel, oral, single-entity (without acetaminophen) extended-release formulation of various strengths of hydrocodone intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. We submitted a New Drug Application to the FDA for Zohydro in May 2012.

Our second DosePro investigational product candidate, Relday, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia.

Manufacturing
SUMAVEL^® DosePro^®

A behind-the-scenes look of how SUMAVEL DosePro is manufactured. It delivers fast acting therapy that patients can self-administer in three easy steps. Watch the video

SUMAVEL^® DosePro^®

SUMAVEL DosePro utilizes our proprietary DosePro needle-free drug delivery system to subcutaneously administer sumatriptan for the acute treatment of migraine and cluster headache. Sumavel DosePro is a fast acting therapy that patients can self-administer in three easy steps. Click here to learn more.

For full prescribing information, click here.